AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04267146
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg
Trial: NCT04267146
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).
Trial: NCT03272425
Drug: allopurinol 300 mg
RxNorm normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator 2
Trial: NCT04248270
Drug: 18F-PM-PBB3
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
Trial: NCT01140906
Drug: Vortioxetine (Lu AA21004)
RxNorm normalized name: Vortioxétine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: encapsulated tablets, daily, orally
Trial: NCT01140906
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: encapsulated capsules, daily, orally
Trial: NCT01781897
Drug: mosapride
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
Trial: NCT02112734
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU/daily until age 12 months
Trial: NCT00113165
Drug: LAMICTAL extended-release
RxNorm normalized name: lamotrigine Extended Release Oral Tablet [Lamictal]
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01122862
Drug: 0.12% chlorhexidine mouthrinse
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: commercially available 0.12% chlorhexidine mouthrinse
Trial: NCT01509131
Drug: 2L PEG-CS plus bisacodyl
RxNorm normalized name: BISACODYL/ELECTROLYTES/PEG-3350
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
Trial: NCT00634517
Drug: Armstrong Albuterol Sulfate Inhalation Aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
Trial: NCT00634517
Drug: Albuterol Sulfate Inhalation Aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
Trial: NCT02043977
Drug: propofol injectable emulsion
RxNorm normalized name: Propofol Injectable Emulsion
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01509131
Drug: 2L PEG-ASC
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will asked to take PEG-ASC according to labeling instructions
Trial: NCT03296579
Drug: Ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized q6h
Trial: NCT03296579
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg/kg IV, 4 doses q6h
Trial: NCT03296579
Drug: Aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg/kg IV (if no progress)
Trial: NCT03349463
Drug: Fluciclovine F18
RxNorm normalized name: FLUCICLOVINE F18 (9-221 MCI/ML) INJ
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All study participants will receive 10 mCi of 18F-Fluciclovine (Axumin) one time administered through injection through the catheter into participant's arm immediately before PET/CT scan.
Trial: NCT03296579
Drug: Standard steroid dose, hourly salbutamol, oxygen as needed
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard common therapies for all three arms.
Trial: NCT00006221
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01144117
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin 48000 IU given I.V. in 17 courses
Trial: NCT04265001
Drug: Hyaluronic acid in the form of hyaluronan sodium 25 mg/100 ml as a mouthwash
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mouthwash used three times daily for one week and patients were not allowed to eat or drink for one hour after rinsing.
Trial: NCT00339053
Drug: Immunonutrition ( Impact)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02186028
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit D 400 IU vs. Vit D 200 IU
Trial: NCT00026130
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
Trial: NCT00089648
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
Trial: NCT04183101
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.
Trial: NCT04183101
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.
Trial: NCT01917019
Drug: BIIB041 (fampridine)
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fampridine prolonged-release tablets
Trial: NCT03257267
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV) administration every 3 weeks (Q3W)
Trial: NCT00003263
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01725542
Drug: Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00596492
Drug: DYME
RxNorm normalized name: Dymelor
DrugBank: Acetohexamide (DB00414)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
Trial: NCT00596492
Drug: DYME
RxNorm normalized name: Dymelor
DrugBank: Acetohexamide (DB00414)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
Trial: NCT01874860
Drug: Hydrocortisone 1% cream
RxNorm normalized name: HYDROCORTISONE 1% CREAM
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
Trial: NCT04259073
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
Trial: NCT04259073
Drug: Pregabalin 300mg
RxNorm normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
Trial: NCT00544388
Drug: levocetirizine dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00756470
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
Trial: NCT00756470
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m\^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
Trial: NCT00756470
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
Trial: NCT03531905
Drug: Bempedoic acid + Ezetimibe FDC Oral Tablet
RxNorm normalized name: bempedoic acid / ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
Trial: NCT03531905
Drug: Ezetimibe 10 mg Oral Tablet
RxNorm normalized name: EZETIMIBE 10 mg ORAL TABLET
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
Trial: NCT00756470
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
Trial: NCT03434782
Drug: Low Level Laser Therapy
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
Trial: NCT03434782
Drug: 5% potassium nitrate / 2% sodium fluoride gel
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
Trial: NCT00259987
Drug: Lapatinib (GW572016) oral tablets
RxNorm normalized name: lapatinib Oral Tablet
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00521560
Drug: Zevalin
RxNorm normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM
Trial: NCT01260974
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/dd for 21dd, starting within 24h from Liver Transplantation.
Trial: NCT01400100
Drug: Intraarterial application of Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
Trial: NCT01394770
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
Trial: NCT02215460
Drug: FMS chlorhexidine rinse
RxNorm normalized name: chlorhexidine gluconate Mouthwash [Denti-Rinse]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT01749371
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
Trial: NCT03961256
Drug: Exenatide SR
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide SR 2 mg subcutaneous (SQ) weekly
Trial: NCT02215460
Drug: QS chlorhexidine rinse
RxNorm normalized name: chlorhexidine gluconate Mouthwash [Denti-Rinse]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
Trial: NCT02892409
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin capsules
Trial: NCT02892409
Drug: Tripotassium bismuth dicitrate
RxNorm normalized name: bismuth
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tripotassium bismuth dicitrate tablets
Trial: NCT02892409
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole capsules
Trial: NCT02892409
Drug: TAK-438
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 tablets
Trial: NCT01136772
Drug: haloperidol decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: haloperidol decanoate injections, 25-200 mg once a month
Trial: NCT01136772
Drug: paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate injections, 39 mg - 234 mg once a month
Trial: NCT02014623
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01662115
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
Trial: NCT00009620
Drug: Phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
Trial: NCT00009620
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of normal sal
Trial: NCT02609490
Drug: Azilsartan tablets
RxNorm normalized name: azilsartan Oral Tablet
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20mg/tablet
Trial: NCT02609490
Drug: Olmesartan medoxomil tablets
RxNorm normalized name: Olmesartan Medoxomil Tablets
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/tablet
Trial: NCT02609490
Drug: olmesartan medoxomil placebo tablets
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT02367560
Drug: Depo medrol
RxNorm normalized name: Depo-Medrol
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
Trial: NCT01847118
Drug: Sevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00189033
Drug: wheat bran (dietary supplement)
RxNorm normalized name: WHEAT BRAN
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00189033
Drug: rice wheat (placebo)
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03299257
Drug: donepezil treatment
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-day donepezil treatment
Trial: NCT04143750
Drug: [14C]Vicagrel
DrugBank: Vicagrel (DB16349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes
Trial: NCT00539890
Drug: Technosphere Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03118674
Drug: Harvoni
RxNorm normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
Trial: NCT00666770
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
Trial: NCT00027781
Drug: sabarubicin
RxNorm normalized name: Sabarubicin
DrugBank: Sabarubicin (DB12410)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00666770
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
Trial: NCT00900562
Drug: Zalypsis ( PM00104)
RxNorm normalized name: Zalypsis
DrugBank: Zalypsis (DB12454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
Trial: NCT00751127
Drug: timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop in the affected eye twice daily for six months.
Trial: NCT03098979
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg orally once daily for 20 weeks
Trial: NCT03098979
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg orally once daily for 20 weeks
Trial: NCT03098979
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg orally once daily for 20 weeks
Trial: NCT03098979
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg orally once daily for 20 weeks
Trial: NCT03098979
Drug: Neladenoson bialanate (BAY1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg orally once daily for 20 weeks
Trial: NCT02369653
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02338037
Drug: Eribulin Mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00883727
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of stem cells
Trial: NCT02362022
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
Trial: NCT01126424
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet